Multiple Sclerosis

Biogen Idec continues to expand its leadership position in MS led by our blockbuster products TYSABRI and AVONEX. In 2011, we announced positive phase III and phase IIb readouts for BG-12 and daclizumab-HYP, respectively, and launched FAMPYRA outside the U.S.

The FDA and EMA regulatory submissions for BG-12 were submitted in the first quarter of 2012 and were a significant step toward the realization of our goal to potentially launch multiple, high-impact therapies in the coming years. Our MS pipeline is one of the strongest in the industry, and we remain dedicated to finding new therapies and expanding the reach of existing ones, as we pursue our mission of improving the lives of people living with MS.